Judith Balmaña Gelpí

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline

Nadine Tung, Judy C. Boughey, Lori J. Pierce et al. · Journal of Clinical Oncology · 2020 · 324 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline <i>BRCA1/2</i> mutations (ABRAZO).

Nicholas C. Turner, Melinda L. Telli, Hope S. Rugo et al. · Journal of Clinical Oncology · 2017 · 54 citations

Medicine, Oncology, Pharmacology +17

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

Karen A. Gelmon, Peter A. Fasching, Fergus J. Couch et al. · European Journal of Cancer · 2021 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17

OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline <i>BRCA1/2 </i>mutations and high-risk HER2-negative early breast cancer.

Andrew Tutt, Judy E. Garber, Bella Kaufman et al. · Journal of Clinical Oncology · 2021 · 32 citations

Medicine, Oncology, Pharmacology +17